Video
Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC
Author(s):
H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.
H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non—small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso), which is now being explored in the FLAURA trial as a frontline treatment.
<<<
Related Videos
Related Content
